Patrick A. Mayes's most recent trade in Incyte Corp. was a trade of 2,207 Common Stock done at an average price of $106.5 . Disclosure was reported to the exchange on Aug. 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.47 per share. | 05 Aug 2026 | 2,207 | 63,648 (0%) | 0% | 106.5 | 234,979 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2026 | 2,207 | 0 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 123.99 per share. | 05 Aug 2026 | 2,207 | 61,441 (0%) | 0% | 124.0 | 273,646 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 119.46 per share. | 31 Jul 2026 | 14,661 | 88,679 (0%) | 0% | 119.5 | 1,751,403 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 9,459 | 0 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.27 per share. | 31 Jul 2026 | 9,459 | 86,218 (0%) | 0% | 72.3 | 683,602 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 119.43 per share. | 31 Jul 2026 | 6,171 | 74,989 (0%) | 0% | 119.4 | 737,003 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 6,055 | 0 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 120.43 per share. | 31 Jul 2026 | 6,055 | 61,441 (0%) | 0% | 120.4 | 729,204 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.43 per share. | 31 Jul 2026 | 6,055 | 67,496 (0%) | 0% | 105.4 | 638,379 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 119.42 per share. | 31 Jul 2026 | 5,332 | 83,347 (0%) | 0% | 119.4 | 636,747 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 119.39 per share. | 31 Jul 2026 | 4,695 | 70,294 (0%) | 0% | 119.4 | 560,536 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 3,148 | 0 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 68.62 per share. | 31 Jul 2026 | 3,148 | 74,687 (0%) | 0% | 68.6 | 216,016 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 3,023 | 202 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 83.20 per share. | 31 Jul 2026 | 3,023 | 96,371 (0%) | 0% | 83.2 | 251,514 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 2,918 | 1,328 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.18 per share. | 31 Jul 2026 | 2,918 | 66,546 (0%) | 0% | 61.2 | 178,523 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 2,864 | 191 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 119.40 per share. | 31 Jul 2026 | 2,864 | 67,430 (0%) | 0% | 119.4 | 341,962 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.67 per share. | 31 Jul 2026 | 2,864 | 91,705 (0%) | 0% | 77.7 | 222,447 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 2,709 | 1,233 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.76 per share. | 31 Jul 2026 | 2,709 | 71,539 (0%) | 0% | 61.8 | 167,308 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 2,623 | 0 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 2,623 | 0 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 83.58 per share. | 31 Jul 2026 | 2,623 | 98,994 (0%) | 0% | 83.6 | 219,230 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.78 per share. | 31 Jul 2026 | 2,623 | 88,841 (0%) | 0% | 74.8 | 196,148 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 2,293 | 0 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 119.41 per share. | 31 Jul 2026 | 2,293 | 61,441 (0%) | 0% | 119.4 | 273,807 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 90.56 per share. | 31 Jul 2026 | 2,293 | 102,929 (0%) | 0% | 90.6 | 207,654 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 2,284 | 2,938 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 64.25 per share. | 31 Jul 2026 | 2,284 | 68,830 (0%) | 0% | 64.3 | 146,747 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 119.47 per share. | 31 Jul 2026 | 2,187 | 81,160 (0%) | 0% | 119.5 | 261,281 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 2,072 | 2,665 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 71.93 per share. | 31 Jul 2026 | 2,072 | 76,759 (0%) | 0% | 71.9 | 149,039 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 1,643 | 0 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 119.51 per share. | 31 Jul 2026 | 1,643 | 65,787 (0%) | 0% | 119.5 | 196,355 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 80.50 per share. | 31 Jul 2026 | 1,643 | 93,348 (0%) | 0% | 80.5 | 132,262 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 1,642 | 0 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 119.38 per share. | 31 Jul 2026 | 1,642 | 64,145 (0%) | 0% | 119.4 | 196,022 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.01 per share. | 31 Jul 2026 | 1,642 | 100,636 (0%) | 0% | 85.0 | 139,586 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 326 | 6,055 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 121.69 per share. | 31 Jul 2026 | 326 | 63,734 (0%) | 0% | 121.7 | 39,671 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.43 per share. | 31 Jul 2026 | 326 | 103,340 (0%) | 0% | 105.4 | 34,370 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2026 | 85 | 2,207 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 122.19 per share. | 31 Jul 2026 | 85 | 64,060 (0%) | 0% | 122.2 | 10,386 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.47 per share. | 31 Jul 2026 | 85 | 103,014 (0%) | 0% | 106.5 | 9,050 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2026 | 25,538 | 25,538 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2026 | 14,790 | 14,790 | - | - | Performance Shares | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2026 | 5,916 | 63,628 (0%) | 0% | 0 | Common Stock | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.09 per share. | 14 Jul 2026 | 1,512 | 57,712 (0%) | 0% | 115.1 | 174,016 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 114.88 per share. | 14 Jul 2026 | 437 | 59,224 (0%) | 0% | 114.9 | 50,203 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 116.86 per share. | 02 Jul 2026 | 350 | 59,661 (0%) | 0% | 116.9 | 40,901 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2026 | 4,218 | 4,218 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 95.58 per share. | 10 Dec 2025 | 5,553 | 60,266 (0%) | 0% | 95.6 | 530,756 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 94.94 per share. | 10 Dec 2025 | 255 | 60,011 (0%) | 0% | 94.9 | 24,210 | Common Stock |
| Incyte | Patrick A. Mayes | EVP & Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.70 per share. | 01 Oct 2025 | 1,569 | 65,819 (0%) | 0% | 86.7 | 136,032 | Common Stock |